With life-threatening food allergies on the rise, drug companies ramp up new approaches
date:Sep 28, 2018
But I think you lose some efficacy because of that more modest approach.

He's more bullish on Aimmune's prospects.

One of the things I like about Aimmune is you walk out of the physician's office knowing how much your kid can tolerate, Skorney said. The data for Aimmune is much clearer; there's much more of a magnitude of benefit.

Targeting the allergen

Smaller biotech companies aren't the only ones working on new approaches to allergy; biotech giant Regeneron is also making a major push in

07/19 00:34